Testing oral roflumilast for moderate to severe psoriasis in adults
Tests oral roflumilast, a pill, in adults with moderate to severe psoriasis.
Plain-language title generated from the registry record
Registry title: A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
Key facts
- Where
- Al Mansurah, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- Mansoura university HospitalAl Mansurah, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ahmed Ibrahim
- Trial code
- NCT07233291
- Record updated
- 2 December 2025
- Original description
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in adults with moderate-to-severe plaque psoriasis. All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12. Secondary outcomes include change in body mass index (BMI) and safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups.Read full original descriptionShow less
Evaluation of Efficacy and Safety of Oral Roflumilast in Treatment of Moderate to Severe Psoriasis: a Pilot Study
This is a 12-week, single-arm, open-label pilot study to assess the safety and preliminary efficacy of oral roflumilast in adults with moderate-to-severe plaque psoriasis. All participants, both male and female, will receive oral roflumilast starting at 250 mcg once daily for 10 days, followed by 500 mcg once daily for the remainder of the study. The primary outcome is the mean change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12. Secondary outcomes include change in body mass index (BMI) and safety assessments, including treatment-emergent adverse events, serious adverse events, and laboratory abnormalities. Male and female participants will be analyzed as subgroups.
Inclusion: Psoriatic patients ≥ 18 years in whom systemic therapy is indicated; Chronic stable plaque psoriasis; Patients who don't use other systemic therapy for psoriasis in the last 2 months (or naïve who didn't use any systemic therapy before); Safe contraception during the study.
Exclusion: Other concomitant psoriasis systemic treatments such as Acitretin and biologics; Previous systemic treatment of psoriasis in the last 2 months; Patients receiving inducers or inhibitors of cytochromes CYP3A4 and CYP1A; Other systemic diseases other than COPD, especially hepatic impairment; Hypersensitivity to the active substance of roflumilast or to any of its excipients; Age <18 years; Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception; The use of contraception with gestodene and ethinylestradiol; Unreliable patients.